Search filters

Filters
Clear All

Phase

  • 33
  • 92
  • 1
  • 77
  • 37
  • 1
  • 93
  • 357
  • 158
  • 13
  • 16
  • 328
  • 354
  • 3

Found 357 Neoplasms trials

A listing of Neoplasms medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

 Maintenance Therapy in Patients with Multiple Myeloma (MM) Using Minimal Residual Disease (DRAMMATIC Study)
17 years - 75 years
All genders
Interventional
This study will examine whether adding the drug daratumumab/rHuPH20 to the usual maintenance treatment with lenalidomide after stem cell transplant help multiple myeloma patients survive longer. For patients who do not have minimum residual disease [MRD-negative], this study is also trying to determine if maintenance therapy should be stopped after …
 A Study to Evaluate the Safety of bb2121 in Subjects With High Risk, Newly Diagnosed Multiple Myeloma (NDMM) (KarMMa-4)
18 years - 99 years
All genders
This is a multicenter, open-label, phase 1, single arm study intended to determine the optimal target dose and safety of bb2121 in subjects with HR (R-ISS Stage III per IMWG criteria) NDMM. Subjects should have received 3 Cycles of standard induction therapy prior to undergoing leukapheresis procedure to collect autologous …
 A Study to Evaluate the Effectiveness and Safety of CAEL-101 in Patients With Mayo Stage IIIb AL Amyloidosis
18 years - 99 years
All genders
Phase 3
Interventional
AL (or light chain) amyloidosis begins in the bone marrow where abnormal proteins misfold and create free light chains that cannot be broken down. These free light chains bind together to form amyloid fibrils that build up in the extracellular space of organs, affecting the kidneys, heart, liver, spleen, nervous …
 A Study to Evaluate the Safety, Tolerability, PK, PD, and Clinical Activity of EQ001 in Subjects With aGVHD ( Graft vs Host)
12 years - 99 years
All genders
Phase 1
This is a multi-center study to evaluate the safety, tolerability, PK, PD, and clinical activity of EQ001 in subjects with Acute Graft Versus Host Disease (aGVHD).
 Maintenance Niraparib and Dostarlimab in Advanced Cholangiocarcinoma
18 years - 99 years
All genders
Phase 2
Interventional
A trial, evaluating molecularly selected, immune-based combination therapy in maintenance treatments for advanced cholangiocarcinoma, selecting patients on the homologous recombination deficient (HRD) signature.
 Measurement of B cell maturation antigen-Directed CAR T Cells During TAK-573 Study Participation
1 years - 99 years
Male
Interventional
The primary objective of this pilot study is to explore in a preliminary fashion whether administration of TAK-573 increases the number of BCMA-specific T cells in blood samples from patients with myeloma.
 A Investigational Agents With or Without Pembrolizumab or Pembrolizumab Alone in Participants With Melanoma
18 years - 120 years
All genders
Interventional
A Investigational Agents With or Without Pembrolizumab or Pembrolizumab Alone in Participants With Melanoma
 Tissue Collection for Multiple Myeloma Research
18 years - 99 years
All genders
Interventional
The primary purpose of this research study is to obtain specimens (blood, bone marrow, and other tissues) for research about multiple myeloma and related diseases.
 A Randomized Study Comparing Venetoclax and Azacitidine to Induction  Chemotherapy for Newly Diagnosed Fit Adults with Acute Myeloid Leukemia
18 years - 99 years
All genders
Phase 2
Interventional
This research is being done to see how an investigational combination of study drugs works in comparison to chemotherapy in people with acute myeloid leukemia. This study involves the following study drug combinations. You will only receive one of these combinations: • Venetoclax and azacitidine (investigational combination) • Cytarabine and …
 A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Participants With Multiple Myeloma (CARTITUDE-2)
18 years - 99 years
All genders
Interventional
The purpose of this study is to see if JNJ-68284528 is safe and useful for treating patients with relapsed or refractory multiple myeloma.
171 - 180 of 357